MAP2K7 and metastatic melanoma: The first clinical studies on the subject were recently performed by Fuca G et al. The first trial demonstrated that patients with metastatic melanoma with high PIV are associated with poor survival rates and also associated with poor treatment response to targeted therapies (BRAF/MEK inhibitors) and immunotherapies.